HEADER    IMMUNOGLOBULIN                          23-DEC-98   1IGA              
TITLE     MODEL OF HUMAN IGA1 DETERMINED BY SOLUTION SCATTERING CURVE-          
TITLE    2 FITTING AND HOMOLOGY MODELLING                                       
COMPND    MOL_ID: 1;                                                            
COMPND   2 MOLECULE: IGA1;                                                      
COMPND   3 CHAIN: A, B;                                                         
COMPND   4 FRAGMENT: CHAINS A AND B, HEAVY, CHAINS C AND D, LIGHT;              
COMPND   5 MOL_ID: 2;                                                           
COMPND   6 MOLECULE: IGA1;                                                      
COMPND   7 CHAIN: C, D;                                                         
COMPND   8 FRAGMENT: CHAINS A AND B, HEAVY, CHAINS C AND D, LIGHT               
SOURCE    MOL_ID: 1;                                                            
SOURCE   2 ORGANISM_SCIENTIFIC: HOMO SAPIENS;                                   
SOURCE   3 ORGANISM_COMMON: HUMAN;                                              
SOURCE   4 ORGANISM_TAXID: 9606;                                                
SOURCE   5 OTHER_DETAILS: SEE PRIMARY REFERENCE FOR MORE DETAILS;               
SOURCE   6 MOL_ID: 2;                                                           
SOURCE   7 ORGANISM_SCIENTIFIC: HOMO SAPIENS;                                   
SOURCE   8 ORGANISM_COMMON: HUMAN;                                              
SOURCE   9 ORGANISM_TAXID: 9606;                                                
SOURCE  10 OTHER_DETAILS: SEE PRIMARY REFERENCE FOR MORE DETAILS                
KEYWDS    IMMUNOGLOBULIN, IGA1                                                  
EXPDTA    SOLUTION SCATTERING                                                   
MDLTYP    CA ATOMS ONLY, CHAIN A, B, C, D                                       
AUTHOR    M.K.BOEHM,J.M.WOOF,M.A.KERR,S.J.PERKINS                               
REVDAT   3   07-APR-10 1IGA    1       REMARK                                   
REVDAT   2   24-FEB-09 1IGA    1       VERSN                                    
REVDAT   1   15-JUN-99 1IGA    0                                                
JRNL        AUTH   M.K.BOEHM,J.M.WOOF,M.A.KERR,S.J.PERKINS                      
JRNL        TITL   THE FAB AND FC FRAGMENTS OF IGA1 EXHIBIT A                   
JRNL        TITL 2 DIFFERENT ARRANGEMENT FROM THAT IN IGG: A STUDY BY           
JRNL        TITL 3 X-RAY AND NEUTRON SOLUTION SCATTERING AND HOMOLOGY           
JRNL        TITL 4 MODELLING.                                                   
JRNL        REF    J.MOL.BIOL.                   V. 286  1421 1999              
JRNL        REFN                   ISSN 0022-2836                               
JRNL        PMID   10064707                                                     
JRNL        DOI    10.1006/JMBI.1998.2556                                       
REMARK   1                                                                      
REMARK   1 REFERENCE 1                                                          
REMARK   1  AUTH   S.J.PERKINS,A.W.ASHTON,M.K.BOEHM,D.CHAMBERLAIN               
REMARK   1  TITL   MOLECULAR STRUCTURES FROM LOW ANGLE X-RAY AND                
REMARK   1  TITL 2 NEUTRON SCATTERING STUDIES                                   
REMARK   1  REF    INT.J.BIOL.MACROMOL.          V.  22     1 1998              
REMARK   1  REFN                   ISSN 0141-8130                               
REMARK   1 REFERENCE 2                                                          
REMARK   1  AUTH   S.J.PERKINS,C.G.ULLMAN,N.C.BRISSETT,D.CHAMBERLAIN,           
REMARK   1  AUTH 2 M.K.BOEHM                                                    
REMARK   1  TITL   ANALOGY AND SOLUTION SCATTERING MODELLING: NEW               
REMARK   1  TITL 2 STRUCTURAL STRATEGIES FOR THE MULTIDOMAIN PROTEINS           
REMARK   1  TITL 3 OF COMPLEMENT, CARTILAGE AND THE IMMUNOGLOBULIN              
REMARK   1  TITL 4 SUPERFAMILY                                                  
REMARK   1  REF    IMMUNOL.REV.                  V. 163   237 1998              
REMARK   1  REFN                   ISSN 0105-2896                               
REMARK   2                                                                      
REMARK   2 RESOLUTION. NOT APPLICABLE.                                          
REMARK   3                                                                      
REMARK   3 REFINEMENT.                                                          
REMARK   3   PROGRAM     : DISCOVER V. 3.0                                      
REMARK   3   AUTHORS     :                                                      
REMARK   3                                                                      
REMARK   3  NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT.                    
REMARK   3   PROTEIN ATOMS            : 1378                                    
REMARK   3   NUCLEIC ACID ATOMS       : 0                                       
REMARK   3   HETEROGEN ATOMS          : 0                                       
REMARK   3   SOLVENT ATOMS            : 0                                       
REMARK   3                                                                      
REMARK   3  OTHER REFINEMENT REMARKS: NULL                                      
REMARK   4                                                                      
REMARK   4 1IGA COMPLIES WITH FORMAT V. 3.15, 01-DEC-08                         
REMARK 100                                                                      
REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY BNL.                                
REMARK 265                                                                      
REMARK 265 EXPERIMENTAL DETAILS                                                 
REMARK 265                                                                      
REMARK 265 EXPERIMENT TYPE : SMALL ANGLE X-RAY SCATTERING                       
REMARK 265  DATA ACQUISITION                                                    
REMARK 265   RADIATION/NEUTRON SOURCE                 : SRS DARESBURY           
REMARK 265   SYNCHROTRON (Y/N)                        : Y                       
REMARK 265   BEAMLINE TYPE                            : 2.1                     
REMARK 265   BEAMLINE INSTRUMENT                      : NULL                    
REMARK 265   DETECTOR TYPE                            : QUADRANT DETECTOR       
REMARK 265   DETECTOR MANUFACTURER DETAILS            : NULL                    
REMARK 265   TEMPERATURE (KELVIN)                     : NULL                    
REMARK 265   PH                                       : NULL                    
REMARK 265   NUMBER OF TIME FRAMES USED               : 1                       
REMARK 265   PROTEIN CONCENTRATION RANGE (MG/ML)      : NULL                    
REMARK 265   SAMPLE BUFFER                            : NULL                    
REMARK 265   DATA REDUCTION SOFTWARE                  : OTOKO                   
REMARK 265   GUINIER MEAN RADIUS OF GYRATION (NM)     : NULL                    
REMARK 265   SIGMA MEAN RADIUS OF GYRATION            : NULL                    
REMARK 265   R(XS-1) MEAN CROSS SECTIONAL RADII (NM)  : NULL                    
REMARK 265   R(XS-1) SIGMA MEAN CROSS SECTIONAL RADII : NULL                    
REMARK 265   R(XS-2) MEAN CROSS SECTIONAL RADII (NM)  : NULL                    
REMARK 265   R(XS-2) SIGMA MEAN CROSS SECTIONAL RADII : NULL                    
REMARK 265   P(R) PROTEIN LENGTH (NM)                 : NULL                    
REMARK 265                                                                      
REMARK 265 EXPERIMENT TYPE : SMALL ANGLE NEUTRON SCATTERING                     
REMARK 265  DATA ACQUISITION                                                    
REMARK 265   RADIATION/NEUTRON SOURCE                 : ISIS RUTHERFORD         
REMARK 265   SYNCHROTRON (Y/N)                        : Y                       
REMARK 265   BEAMLINE TYPE                            : LOQ                     
REMARK 265   BEAMLINE INSTRUMENT                      : NULL                    
REMARK 265   DETECTOR TYPE                            : HE-3 ORDELA             
REMARK 265                                              DETECTOR                
REMARK 265   DETECTOR MANUFACTURER DETAILS            : NULL                    
REMARK 265   TEMPERATURE (KELVIN)                     : NULL                    
REMARK 265   PH                                       : NULL                    
REMARK 265   NUMBER OF TIME FRAMES USED               : 1                       
REMARK 265   PROTEIN CONCENTRATION RANGE (MG/ML)      : NULL                    
REMARK 265   SAMPLE BUFFER                            : NULL                    
REMARK 265   DATA REDUCTION SOFTWARE                  : COLETTE                 
REMARK 265   GUINIER MEAN RADIUS OF GYRATION (NM)     : NULL                    
REMARK 265   SIGMA MEAN RADIUS OF GYRATION            : NULL                    
REMARK 265   R(XS-1) MEAN CROSS SECTIONAL RADII (NM)  : NULL                    
REMARK 265   R(XS-1) SIGMA MEAN CROSS SECTIONAL RADII : NULL                    
REMARK 265   R(XS-2) MEAN CROSS SECTIONAL RADII (NM)  : NULL                    
REMARK 265   R(XS-2) SIGMA MEAN CROSS SECTIONAL RADII : NULL                    
REMARK 265   P(R) PROTEIN LENGTH (NM)                 : NULL                    
REMARK 265                                                                      
REMARK 265 DATA ANALYSIS AND MODEL FITTING:                                     
REMARK 265  METHOD USED TO DETERMINE THE STRUCTURE: SCATTERING FITTING,         
REMARK 265                                          ENERGY MINIMIZATION         
REMARK 265  SOFTWARE USED    : INSIGHT II, DISCOVERY 2.9.7, BIOSYM              
REMARK 265  SOFTWARE AUTHORS : NULL                                             
REMARK 265  STARTING MODEL   : NULL                                             
REMARK 265                                                                      
REMARK 265 CONFORMERS, NUMBER CALCULATED   : NULL                               
REMARK 265 CONFORMERS, NUMBER SUBMITTED    : 1                                  
REMARK 265 CONFORMERS, SELECTION CRITERIA  : NULL                               
REMARK 265                                                                      
REMARK 265 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : 1                   
REMARK 265                                                                      
REMARK 265  OTHER DETAILS: THE MODEL OF HUMAN IGA1 WAS BASED ON SEVERAL         
REMARK 265  IMMUNOGLOBULIN CRYSTAL STRUCTURES FROM THE PDB. AN IGA1             
REMARK 265  MONOMER CONTAINS TWELVE DOMAINS ON TWO FOUR-DOMAIN HEAVY            
REMARK 265  CHAINS AND TWO TWO-DOMAIN LIGHT CHAINS. THE CHAINS ASSOCIATE        
REMARK 265  TO FORM TWO FOUR-DOMAIN FAB FRAGMENTS AND ONE FOUR-DOMAIN FC        
REMARK 265  FRAGMENT. EACH FAB FRAGMENT IS JOINED TO THE FC FRAGMENT BY A       
REMARK 265  23-RESIDUE PEPTIDE LINKER. THERE ARE SIX DOMAIN TYPES IN IGA1       
REMARK 265  (VH, CH1, CH2, CH3, VL AND CL), AND A MONOMER CONTAINS TWO          
REMARK 265  COPIES OF EACH DOMAIN-TYPE. THE SEQUENCES OF THE CH1, CH2 AND       
REMARK 265  CH3 DOMAINS ARE SPECIFIC TO IGA1. REFINEMENT WAS CARRIED OUT        
REMARK 265  USING DISCOVER 2.9.7, BIOSYM. ALSO USED ENERGY MINIMISATION.        
REMARK 265  THE IGA1 CH1 DOMAIN WAS MODELLED USING THE CORRESPONDING            
REMARK 265  DOMAIN FROM THE THE MOUSE IGA J539 FAB STRUCTURE (CODE: 2FBJ)       
REMARK 265  AND THE HUMAN IGG1 TR1.9 FAB STRUCTURE (CODE: 1VGE) AS              
REMARK 265  TEMPLATES. THE IGA1 CH2 AND CH3 DOMAINS WERE MODELLED USING         
REMARK 265  THE CORRESPONDING DOMAINS FROM THE HUMAN IGG1 FC STRUCTURE          
REMARK 265  (CODE: 1FC1) AS TEMPLATES. THE REMAINING DOMAINS IN THE IGA1        
REMARK 265  MODEL (VL, CL AND VH) USED THE APPROPRIATE DOMAINS FROM THE         
REMARK 265  TR1.9 FAB STRUCTURE DIRECTLY. EACH FAB FRAGMENT CONTAINS A          
REMARK 265  SINGLE COPY OF THE VH, CH1, VL AND CL DOMAINS, AND THEIR            
REMARK 265  ARRANGEMENT WAS BASED DIRECTLY ON THE TR1.9 FAB STRUCTURE. IN       
REMARK 265  THE FC STRUCTURE, TWO COPIES OF THE CH2 AND CH3 DOMAINS WERE        
REMARK 265  USED. THEIR ARRANGEMENT WAS BASED ON THAT IN THE HUMAN IGG1 FC      
REMARK 265  STRUCTURE (CODE 1FC1) EXCEPT THAT THE TWO CH2 DOMAINS WERE          
REMARK 265  REORIENTATED AND REMODELLED SLIGHTLY TO ACCOMMODATE A PROPOSED      
REMARK 265  DISULPHIDE BRIDGING PATTERN. THE POSITIONS OF THE FAB               
REMARK 265  FRAGMENTS RELATIVE TO THE FC FRAGMENT WERE DETERMINED BY AN         
REMARK 265  APPROACH THAT COMBINED RANDOM HINGE PEPTIDE STRUCTURES              
REMARK 265  PRODUCED BY MOLECULAR DYNAMICS SIMULATIONS WITH CURVE-FITTING       
REMARK 265  TO EXPERIMENTAL SOLUTION SCATTERING DATA. A SINGLE ARRANGEMENT      
REMARK 265  OF THE FAB FRAGMENTS IS PRESENTED, WHICH IS REPRESENTATIVE OF       
REMARK 265  A FAMILY OF STRUCTURES THAT FIT THE SCATTERING DATA. IN             
REMARK 265  ADDITION, IGA1 CONTAINS AN 18-RESIDUE TAILPIECE PEPTIDE AT THE      
REMARK 265  C-TERMINAL OF EACH CH3 DOMAIN. THE TAILPIECE STRUCTURE              
REMARK 265  PRODUCED BY MOLECULAR DYNAMICS SIMULATIONS THAT BEST-FITTED         
REMARK 265  THE EXPERIMENTAL DATA IS SHOWN ON EACH MODEL. MORE DETAILS ON       
REMARK 265  THE MODELLING STRATEGY ARE CONTAINED IN THE PRIMARY REFERENCE.      
REMARK 300                                                                      
REMARK 300 BIOMOLECULE: 1                                                       
REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM                
REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN                  
REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON               
REMARK 300 BURIED SURFACE AREA.                                                 
REMARK 350                                                                      
REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN           
REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE                
REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS          
REMARK 350 GIVEN BELOW.  BOTH NON-CRYSTALLOGRAPHIC AND                          
REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN.                               
REMARK 350                                                                      
REMARK 350 BIOMOLECULE: 1                                                       
REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TETRAMERIC                        
REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, C, D                            
REMARK 350   BIOMT1   1  1.000000  0.000000  0.000000        0.00000            
REMARK 350   BIOMT2   1  0.000000  1.000000  0.000000        0.00000            
REMARK 350   BIOMT3   1  0.000000  0.000000  1.000000        0.00000            
DBREF  1IGA A  123   475  UNP    P01876   IGHA1_HUMAN      1    353             
DBREF  1IGA B  123   475  UNP    P01876   IGHA1_HUMAN      1    353             
DBREF  1IGA C    1   214  EMBL   X95747   CAA65058        23    234             
DBREF  1IGA D    1   214  EMBL   X95747   CAA65058        23    234             
SEQADV 1IGA VAL C    3  EMBL X95747              INSERTION                      
SEQADV 1IGA MET C    4  EMBL X95747              INSERTION                      
SEQADV 1IGA LEU C   11  EMBL X95747    VAL    31 CONFLICT                       
SEQADV 1IGA ASN C   20  EMBL X95747    THR    40 CONFLICT                       
SEQADV 1IGA ALA C   22  EMBL X95747    THR    42 CONFLICT                       
SEQADV 1IGA ALA C   32  EMBL X95747    TRP    52 CONFLICT                       
SEQADV 1IGA ARG C   45  EMBL X95747    LYS    65 CONFLICT                       
SEQADV 1IGA ASP C   50  EMBL X95747    SER    70 CONFLICT                       
SEQADV 1IGA ASN C   53  EMBL X95747    SER    73 CONFLICT                       
SEQADV 1IGA GLU C   55  EMBL X95747    GLN    75 CONFLICT                       
SEQADV 1IGA THR C   72  EMBL X95747    SER    92 CONFLICT                       
SEQADV 1IGA PHE C   83  EMBL X95747    SER   103 CONFLICT                       
SEQADV 1IGA ILE C   85  EMBL X95747    THR   105 CONFLICT                       
SEQADV 1IGA PHE C   91  EMBL X95747    ALA   111 CONFLICT                       
SEQADV 1IGA TYR C   94  EMBL X95747    PHE   114 CONFLICT                       
SEQADV 1IGA LEU C   96  EMBL X95747    TYR   116 CONFLICT                       
SEQADV 1IGA GLY C  100  EMBL X95747    GLN   120 CONFLICT                       
SEQADV 1IGA VAL C  191  EMBL X95747    LEU   211 CONFLICT                       
SEQADV 1IGA VAL D    3  EMBL X95747              INSERTION                      
SEQADV 1IGA MET D    4  EMBL X95747              INSERTION                      
SEQADV 1IGA LEU D   11  EMBL X95747    VAL    31 CONFLICT                       
SEQADV 1IGA ASN D   20  EMBL X95747    THR    40 CONFLICT                       
SEQADV 1IGA ALA D   22  EMBL X95747    THR    42 CONFLICT                       
SEQADV 1IGA ALA D   32  EMBL X95747    TRP    52 CONFLICT                       
SEQADV 1IGA ARG D   45  EMBL X95747    LYS    65 CONFLICT                       
SEQADV 1IGA ASP D   50  EMBL X95747    SER    70 CONFLICT                       
SEQADV 1IGA ASN D   53  EMBL X95747    SER    73 CONFLICT                       
SEQADV 1IGA GLU D   55  EMBL X95747    GLN    75 CONFLICT                       
SEQADV 1IGA THR D   72  EMBL X95747    SER    92 CONFLICT                       
SEQADV 1IGA PHE D   83  EMBL X95747    SER   103 CONFLICT                       
SEQADV 1IGA ILE D   85  EMBL X95747    THR   105 CONFLICT                       
SEQADV 1IGA PHE D   91  EMBL X95747    ALA   111 CONFLICT                       
SEQADV 1IGA TYR D   94  EMBL X95747    PHE   114 CONFLICT                       
SEQADV 1IGA LEU D   96  EMBL X95747    TYR   116 CONFLICT                       
SEQADV 1IGA GLY D  100  EMBL X95747    GLN   120 CONFLICT                       
SEQADV 1IGA VAL D  191  EMBL X95747    LEU   211 CONFLICT                       
SEQRES   1 A  475  GLN VAL LYS LEU LEU GLU GLN SER GLY ALA GLU VAL LYS          
SEQRES   2 A  475  LYS PRO GLY ALA SER VAL LYS VAL SER CYS LYS ALA SER          
SEQRES   3 A  475  GLY TYR SER PHE THR SER TYR GLY LEU HIS TRP VAL ARG          
SEQRES   4 A  475  GLN ALA PRO GLY GLN ARG LEU GLU TRP MET GLY TRP ILE          
SEQRES   5 A  475  SER ALA GLY THR GLY ASN THR LYS TYR SER GLN LYS PHE          
SEQRES   6 A  475  ARG GLY ARG VAL THR PHE THR ARG ASP THR SER ALA THR          
SEQRES   7 A  475  THR ALA TYR MET GLY LEU SER SER LEU ARG PRO GLU ASP          
SEQRES   8 A  475  THR ALA VAL TYR TYR CYS ALA ARG ASP PRO TYR GLY GLY          
SEQRES   9 A  475  GLY LYS SER GLU PHE ASP TYR TRP GLY GLN GLY THR LEU          
SEQRES  10 A  475  VAL THR VAL SER SER ALA SER PRO THR SER PRO LYS VAL          
SEQRES  11 A  475  PHE PRO LEU SER LEU CYS SER THR GLN PRO ASP GLY ASN          
SEQRES  12 A  475  VAL VAL ILE ALA CYS LEU VAL GLN GLY PHE PHE PRO GLN          
SEQRES  13 A  475  GLU PRO LEU SER VAL THR TRP SER GLU SER GLY GLN GLY          
SEQRES  14 A  475  VAL THR ALA ARG ASN PHE PRO PRO SER GLN ASP ALA SER          
SEQRES  15 A  475  GLY ASP LEU TYR THR THR SER SER GLN LEU THR LEU PRO          
SEQRES  16 A  475  ALA THR GLN CYS LEU ALA GLY LYS SER VAL THR CYS HIS          
SEQRES  17 A  475  VAL LYS HIS TYR THR ASN PRO SER GLN ASP VAL THR VAL          
SEQRES  18 A  475  PRO CYS PRO VAL PRO SER THR PRO PRO THR PRO SER PRO          
SEQRES  19 A  475  SER THR PRO PRO THR PRO SER PRO SER CYS CYS HIS PRO          
SEQRES  20 A  475  ARG LEU SER LEU HIS ARG PRO ALA LEU GLU ASP LEU LEU          
SEQRES  21 A  475  LEU GLY SER GLU ALA ASN LEU THR CYS THR LEU THR GLY          
SEQRES  22 A  475  LEU ARG ASP ALA SER GLY VAL THR PHE THR TRP THR PRO          
SEQRES  23 A  475  SER SER GLY LYS SER ALA VAL GLN GLY PRO PRO GLU ARG          
SEQRES  24 A  475  ASP LEU CYS GLY CYS TYR SER VAL SER SER VAL LEU PRO          
SEQRES  25 A  475  GLY CYS ALA GLU PRO TRP ASN HIS GLY LYS THR PHE THR          
SEQRES  26 A  475  CYS THR ALA ALA TYR PRO GLU SER LYS THR PRO LEU THR          
SEQRES  27 A  475  ALA THR LEU SER LYS SER GLY ASN THR PHE ARG PRO GLU          
SEQRES  28 A  475  VAL HIS LEU LEU PRO PRO PRO SER GLU GLU LEU ALA LEU          
SEQRES  29 A  475  ASN GLU LEU VAL THR LEU THR CYS LEU ALA ARG GLY PHE          
SEQRES  30 A  475  SER PRO LYS ASP VAL LEU VAL ARG TRP LEU GLN GLY SER          
SEQRES  31 A  475  GLN GLU LEU PRO ARG GLU LYS TYR LEU THR TRP ALA SER          
SEQRES  32 A  475  ARG GLN GLU PRO SER GLN GLY THR THR THR PHE ALA VAL          
SEQRES  33 A  475  THR SER ILE LEU ARG VAL ALA ALA GLU ASP TRP LYS LYS          
SEQRES  34 A  475  GLY ASP THR PHE SER CYS MET VAL GLY HIS GLU ALA LEU          
SEQRES  35 A  475  PRO LEU ALA PHE THR GLN LYS THR ILE ASP ARG LEU ALA          
SEQRES  36 A  475  GLY LYS PRO THR HIS VAL ASN VAL SER VAL VAL MET ALA          
SEQRES  37 A  475  GLU VAL ASP GLY THR CYS TYR                                  
SEQRES   1 B  475  GLN VAL LYS LEU LEU GLU GLN SER GLY ALA GLU VAL LYS          
SEQRES   2 B  475  LYS PRO GLY ALA SER VAL LYS VAL SER CYS LYS ALA SER          
SEQRES   3 B  475  GLY TYR SER PHE THR SER TYR GLY LEU HIS TRP VAL ARG          
SEQRES   4 B  475  GLN ALA PRO GLY GLN ARG LEU GLU TRP MET GLY TRP ILE          
SEQRES   5 B  475  SER ALA GLY THR GLY ASN THR LYS TYR SER GLN LYS PHE          
SEQRES   6 B  475  ARG GLY ARG VAL THR PHE THR ARG ASP THR SER ALA THR          
SEQRES   7 B  475  THR ALA TYR MET GLY LEU SER SER LEU ARG PRO GLU ASP          
SEQRES   8 B  475  THR ALA VAL TYR TYR CYS ALA ARG ASP PRO TYR GLY GLY          
SEQRES   9 B  475  GLY LYS SER GLU PHE ASP TYR TRP GLY GLN GLY THR LEU          
SEQRES  10 B  475  VAL THR VAL SER SER ALA SER PRO THR SER PRO LYS VAL          
SEQRES  11 B  475  PHE PRO LEU SER LEU CYS SER THR GLN PRO ASP GLY ASN          
SEQRES  12 B  475  VAL VAL ILE ALA CYS LEU VAL GLN GLY PHE PHE PRO GLN          
SEQRES  13 B  475  GLU PRO LEU SER VAL THR TRP SER GLU SER GLY GLN GLY          
SEQRES  14 B  475  VAL THR ALA ARG ASN PHE PRO PRO SER GLN ASP ALA SER          
SEQRES  15 B  475  GLY ASP LEU TYR THR THR SER SER GLN LEU THR LEU PRO          
SEQRES  16 B  475  ALA THR GLN CYS LEU ALA GLY LYS SER VAL THR CYS HIS          
SEQRES  17 B  475  VAL LYS HIS TYR THR ASN PRO SER GLN ASP VAL THR VAL          
SEQRES  18 B  475  PRO CYS PRO VAL PRO SER THR PRO PRO THR PRO SER PRO          
SEQRES  19 B  475  SER THR PRO PRO THR PRO SER PRO SER CYS CYS HIS PRO          
SEQRES  20 B  475  ARG LEU SER LEU HIS ARG PRO ALA LEU GLU ASP LEU LEU          
SEQRES  21 B  475  LEU GLY SER GLU ALA ASN LEU THR CYS THR LEU THR GLY          
SEQRES  22 B  475  LEU ARG ASP ALA SER GLY VAL THR PHE THR TRP THR PRO          
SEQRES  23 B  475  SER SER GLY LYS SER ALA VAL GLN GLY PRO PRO GLU ARG          
SEQRES  24 B  475  ASP LEU CYS GLY CYS TYR SER VAL SER SER VAL LEU PRO          
SEQRES  25 B  475  GLY CYS ALA GLU PRO TRP ASN HIS GLY LYS THR PHE THR          
SEQRES  26 B  475  CYS THR ALA ALA TYR PRO GLU SER LYS THR PRO LEU THR          
SEQRES  27 B  475  ALA THR LEU SER LYS SER GLY ASN THR PHE ARG PRO GLU          
SEQRES  28 B  475  VAL HIS LEU LEU PRO PRO PRO SER GLU GLU LEU ALA LEU          
SEQRES  29 B  475  ASN GLU LEU VAL THR LEU THR CYS LEU ALA ARG GLY PHE          
SEQRES  30 B  475  SER PRO LYS ASP VAL LEU VAL ARG TRP LEU GLN GLY SER          
SEQRES  31 B  475  GLN GLU LEU PRO ARG GLU LYS TYR LEU THR TRP ALA SER          
SEQRES  32 B  475  ARG GLN GLU PRO SER GLN GLY THR THR THR PHE ALA VAL          
SEQRES  33 B  475  THR SER ILE LEU ARG VAL ALA ALA GLU ASP TRP LYS LYS          
SEQRES  34 B  475  GLY ASP THR PHE SER CYS MET VAL GLY HIS GLU ALA LEU          
SEQRES  35 B  475  PRO LEU ALA PHE THR GLN LYS THR ILE ASP ARG LEU ALA          
SEQRES  36 B  475  GLY LYS PRO THR HIS VAL ASN VAL SER VAL VAL MET ALA          
SEQRES  37 B  475  GLU VAL ASP GLY THR CYS TYR                                  
SEQRES   1 C  214  GLU LEU VAL MET THR GLN SER PRO SER SER LEU SER ALA          
SEQRES   2 C  214  SER VAL GLY ASP ARG VAL ASN ILE ALA CYS ARG ALA SER          
SEQRES   3 C  214  GLN GLY ILE SER SER ALA LEU ALA TRP TYR GLN GLN LYS          
SEQRES   4 C  214  PRO GLY LYS ALA PRO ARG LEU LEU ILE TYR ASP ALA SER          
SEQRES   5 C  214  ASN LEU GLU SER GLY VAL PRO SER ARG PHE SER GLY SER          
SEQRES   6 C  214  GLY SER GLY THR ASP PHE THR LEU THR ILE SER SER LEU          
SEQRES   7 C  214  GLN PRO GLU ASP PHE ALA ILE TYR TYR CYS GLN GLN PHE          
SEQRES   8 C  214  ASN SER TYR PRO LEU THR PHE GLY GLY GLY THR LYS VAL          
SEQRES   9 C  214  GLU ILE LYS ARG THR VAL ALA ALA PRO SER VAL PHE ILE          
SEQRES  10 C  214  PHE PRO PRO SER ASP GLU GLN LEU LYS SER GLY THR ALA          
SEQRES  11 C  214  SER VAL VAL CYS LEU LEU ASN ASN PHE TYR PRO ARG GLU          
SEQRES  12 C  214  ALA LYS VAL GLN TRP LYS VAL ASP ASN ALA LEU GLN SER          
SEQRES  13 C  214  GLY ASN SER GLN GLU SER VAL THR GLU GLN ASP SER LYS          
SEQRES  14 C  214  ASP SER THR TYR SER LEU SER SER THR LEU THR LEU SER          
SEQRES  15 C  214  LYS ALA ASP TYR GLU LYS HIS LYS VAL TYR ALA CYS GLU          
SEQRES  16 C  214  VAL THR HIS GLN GLY LEU SER SER PRO VAL THR LYS SER          
SEQRES  17 C  214  PHE ASN ARG GLY GLU CYS                                      
SEQRES   1 D  214  GLU LEU VAL MET THR GLN SER PRO SER SER LEU SER ALA          
SEQRES   2 D  214  SER VAL GLY ASP ARG VAL ASN ILE ALA CYS ARG ALA SER          
SEQRES   3 D  214  GLN GLY ILE SER SER ALA LEU ALA TRP TYR GLN GLN LYS          
SEQRES   4 D  214  PRO GLY LYS ALA PRO ARG LEU LEU ILE TYR ASP ALA SER          
SEQRES   5 D  214  ASN LEU GLU SER GLY VAL PRO SER ARG PHE SER GLY SER          
SEQRES   6 D  214  GLY SER GLY THR ASP PHE THR LEU THR ILE SER SER LEU          
SEQRES   7 D  214  GLN PRO GLU ASP PHE ALA ILE TYR TYR CYS GLN GLN PHE          
SEQRES   8 D  214  ASN SER TYR PRO LEU THR PHE GLY GLY GLY THR LYS VAL          
SEQRES   9 D  214  GLU ILE LYS ARG THR VAL ALA ALA PRO SER VAL PHE ILE          
SEQRES  10 D  214  PHE PRO PRO SER ASP GLU GLN LEU LYS SER GLY THR ALA          
SEQRES  11 D  214  SER VAL VAL CYS LEU LEU ASN ASN PHE TYR PRO ARG GLU          
SEQRES  12 D  214  ALA LYS VAL GLN TRP LYS VAL ASP ASN ALA LEU GLN SER          
SEQRES  13 D  214  GLY ASN SER GLN GLU SER VAL THR GLU GLN ASP SER LYS          
SEQRES  14 D  214  ASP SER THR TYR SER LEU SER SER THR LEU THR LEU SER          
SEQRES  15 D  214  LYS ALA ASP TYR GLU LYS HIS LYS VAL TYR ALA CYS GLU          
SEQRES  16 D  214  VAL THR HIS GLN GLY LEU SER SER PRO VAL THR LYS SER          
SEQRES  17 D  214  PHE ASN ARG GLY GLU CYS                                      
CRYST1    1.000    1.000    1.000  90.00  90.00  90.00 P 1           1          
ORIGX1      1.000000  0.000000  0.000000        0.00000                         
ORIGX2      0.000000  1.000000  0.000000        0.00000                         
ORIGX3      0.000000  0.000000  1.000000        0.00000                         
SCALE1      1.000000  0.000000  0.000000        0.00000                         
SCALE2      0.000000  1.000000  0.000000        0.00000                         
SCALE3      0.000000  0.000000  1.000000        0.00000                         
